Alatrofloxacin: Difference between revisions
m Protected "Alatrofloxacin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 27: | Line 27: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone]] [[antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] salt.<ref>{{cite web|url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5489474|title=PubChem CID 5489474}}</ref> It is the parental [[prodrug]] of [[trovafloxacin]] (Trovan) meant for [[intravenous therapy|intravenous]] administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.<ref>{{cite journal |author=Hall IH, Schwab UE, Ward ES, Ives TJ |title=Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes |journal=Biomed. Pharmacother. |volume=57 |issue=8 |pages=359–65 |year=2003 |pmid=14568230 |doi=}}</ref><ref>{{cite journal |author=Lenzer J |title=Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests |journal=[[British Medical Journal|BMJ]] |volume=332 |issue=7552 |pages=1233 |year=2006 |pmid=16735322 |doi=10.1136/bmj.332.7552.1233-a}}</ref> | '''Alatrofloxacin''' ('''Trovan IV''') is a [[fluoroquinolone]] [[antibiotic]] developed by [[Pfizer]], delivered as a [[mesylate]] salt.<ref>{{cite web|url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5489474|title=PubChem CID 5489474}}</ref> It is the parental [[prodrug]] of [[trovafloxacin]] (Trovan) meant for [[intravenous therapy|intravenous]] administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.<ref>{{cite journal |author=Hall IH, Schwab UE, Ward ES, Ives TJ |title=Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes |journal=Biomed. Pharmacother. |volume=57 |issue=8 |pages=359–65 |year=2003 |pmid=14568230 |doi=}}</ref><ref>{{cite journal |author=Lenzer J |title=Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests |journal=[[British Medical Journal|BMJ]] |volume=332 |issue=7552 |pages=1233 |year=2006 |pmid=16735322 |doi=10.1136/bmj.332.7552.1233-a}}</ref> | ||
| Line 34: | Line 34: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
[[Category:Fluoroquinolone antibiotics]] | [[Category:Fluoroquinolone antibiotics]] | ||
| Line 40: | Line 40: | ||
[[Category:Withdrawn drugs]] | [[Category:Withdrawn drugs]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 14:13, 4 September 2012
| File:Alatrofloxacin.svg | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Intravenous |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | 76% (trovafloxacin) |
| Metabolism | Quickly hydrolyzed to trovafloxacin |
| Elimination half-life | 9 to 12 hours (trovafloxacin) |
| Excretion | Fecal and renal (trovafloxacin) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C26H25F3N6O5 |
| Molar mass | 558.509 g/mol |
|
WikiDoc Resources for Alatrofloxacin |
|
Articles |
|---|
|
Most recent articles on Alatrofloxacin Most cited articles on Alatrofloxacin |
|
Media |
|
Powerpoint slides on Alatrofloxacin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alatrofloxacin at Clinical Trials.gov Trial results on Alatrofloxacin Clinical Trials on Alatrofloxacin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alatrofloxacin NICE Guidance on Alatrofloxacin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alatrofloxacin Discussion groups on Alatrofloxacin Patient Handouts on Alatrofloxacin Directions to Hospitals Treating Alatrofloxacin Risk calculators and risk factors for Alatrofloxacin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alatrofloxacin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1] It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.[2][3]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
References
- ↑ "PubChem CID 5489474".
- ↑ Hall IH, Schwab UE, Ward ES, Ives TJ (2003). "Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes". Biomed. Pharmacother. 57 (8): 359–65. PMID 14568230.
- ↑ Lenzer J (2006). "Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests". BMJ. 332 (7552): 1233. doi:10.1136/bmj.332.7552.1233-a. PMID 16735322.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Fluoroquinolone antibiotics
- Prodrugs
- Withdrawn drugs